Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.22 USD

3.22
357,505

+0.04 (1.26%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -105.56% and 13.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Biogen Inc. (BIIB) Q1 Earnings Lag Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of -7.36% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Puma Biotech (PBYI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is the Options Market Predicting a Spike in Puma Biotechnology Stock?

by Zacks Equity Research

Investors need to pay close attention to PBYI stock based on the movements in the options market lately.

Zacks Equity Research

Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why

by Zacks Equity Research

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Zacks Equity Research

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

by Zacks Equity Research

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.

Zacks Equity Research

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 207.14% and 14.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Liquidia Technologies (LQDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?

by Zacks Equity Research

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

by Zacks Equity Research

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.

Zacks Equity Research

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

by Zacks Equity Research

Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.

Zacks Equity Research

ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals

by Zacks Equity Research

Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.

Zacks Equity Research

SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

by Zacks Equity Research

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.

Zacks Equity Research

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

by Zacks Equity Research

Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.

Zacks Equity Research

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

by Zacks Equity Research

Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

Zacks Equity Research

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up

by Zacks Equity Research

Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.

Zacks Equity Research

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

by Zacks Equity Research

CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.

Zacks Equity Research

Here's Why You Should Consider Buying Atara Biotherapeutics Stock

by Zacks Equity Research

Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.

Zacks Equity Research

Geron Stock Rallies More Than 60% in a Year: Here's Why

by Zacks Equity Research

FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.

Zacks Equity Research

SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia

by Zacks Equity Research

Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.

Zacks Equity Research

GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.

Zacks Equity Research

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

by Zacks Equity Research

ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.